Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab
Phase of Trial: Phase III
Latest Information Update: 02 Apr 2018
Price : $35 *
At a glance
- Drugs Panitumumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 28 Mar 2018 Planned End Date changed from 18 Dec 2022 to 27 Feb 2023.
- 28 Mar 2018 Planned primary completion date changed from 18 Dec 2021 to 27 Feb 2022.
- 28 Mar 2018 Status changed from not yet recruiting to recruiting.